Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine.
The ability of antisera raised against a candidate Japanese encephalitis virus (JEV) vaccine, ChimeriVax-JE, and the currently licensed vaccine, JE-VAX, to protect against strains of JEV representing the four major genotypes was assessed. Neutralization assays and passive protection studies in mice showed that greatest protection was provided against strains of genotypes II and III, although some protection was also afforded against genotypes I and IV strains. ChimeriVax-JE stimulated protection that was comparable or superior to the JE-VAX control.
Department of Pathology, Sealy Center for Vaccine Development, and Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555-0609, USA. d.beasley@utmb.edu
David W C
DW
Beasley
Li
L
Li
Miguel T
MT
Suderman
Farshad
F
Guirakhoo
Dennis W
DW
Trent
Thomas P
TP
Monath
Robert E
RE
Shope
Alan D T
AD
Barrett
D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis / Q000096:biosynthesis; D004664:Encephalitis Virus, Japanese / Q000235:genetics / Q000276:immunology*; D004672:Encephalitis, Japanese / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D005838:Genotype; D007116:Immunization, Passive; D022321:Japanese Encephalitis Vaccines / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D008813:Mice, Inbred ICR; D009500:Neutralization Tests; D011993:Recombinant Fusion Proteins / Q000276:immunology; D016019:Survival Analysis
D000914:Antibodies, Viral; D022321:Japanese Encephalitis Vaccines; D011993:Recombinant Fusion Proteins